Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of IPX066 vs Standard Carbidopa-Levodopa in Advanced Parkinson's
NCT00869791Phase 2Completed
- Sponsor
- Impax Laboratories
- Start
- Nov 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carbidopa + levodopa in Parkinson's disease (PD) (2 arms), sponsored by Impax Laboratories. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Maximum Plasma Concentration at Day 8 and 1 more. Started Nov 2008; status: completed.
02
Drugs
carbidopa + levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00869791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869791.